Drug intelligence / Profile preview

L-K6

Development stage
Preclinical
Modality
Antimicrobial Peptides → Native Peptides → Peptides
Administration
Intratumoral
01

Overview

L-K6 is a synthetic lysine/leucine-rich cationic antimicrobial peptide (CAP) that is an analog of temporin-1CEb, originally isolated from the skin secretion of the Chinese brown frog, Rana chensinensis. It exhibits broad-spectrum antimicrobial activity against Gram-negative and Gram-positive bacteria, anticancer activity against breast cancer and glioblastoma cells, and anti-inflammatory properties. Its mechanism of action involves permeabilizing bacterial cell membranes, disrupting cancer cell membranes, promoting internalization into cancer cells via endocytosis (caveolae-mediated endocytosis and macropinocytosis), and inducing nuclear damage. For its anti-inflammatory effects, L-K6 neutralizes lipopolysaccharide (LPS) and inhibits inflammatory signaling pathways, specifically the MyD88-dependent pathway, including mitogen-activated protein kinases (MAPKs) and the NF-κB signaling pathway.

Other names
lysine/leucine-rich CAPlysine-/leucine-rich antimicrobial peptidetemporin-1CEb analogtemporin1CEb analogtemporin 1CEb analog
02

Targets

MEKMYD88 (Myeloid differentiation primary response protein MyD88)MUC1 (Mucin-1 Antigen)SA (Sialic acid)

Beyond the preview

Go deeper on L-K6.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on L-K6.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call